NTRA

Natera, Inc.
$396.10
-1.67 (-0.42%)
Mkt Cap 56.67B
Volume 733,193
52W Range 170.815-437.41
Sector Healthcare
Beta 1.50
EPS (TTM) -1.36 USD
P/E Ratio -150.72
Revenue (TTM) 2.71B USD
Rev Growth (5Y) +42.6%
EPS Growth (5Y) N/A
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 2.31B 1.70B 1.08B 820.22M 625.49M 391.00M 302.33M 257.65M 210.94M 217.07M 190.35M 159.29M
Net Income (208.16M) (190.43M) (434.80M) (547.80M) (471.72M) (229.74M) (124.83M) (128.15M) (136.31M) (95.77M) (70.28M) (5.15M)
EPS -1.52 -1.53 -3.78 -5.57 -5.21 -2.84 -1.79 -2.22 -2.56 -1.86 -1.47 -0.14
Free Cash Flow 109.11M 69.24M (286.15M) (479.20M) (376.27M) (202.12M) (68.41M) (74.46M) (106.66M) (97.04M) (45.68M) 533,000
FCF / Share 0.80 0.56 -2.49 -4.87 -4.15 -2.49 -0.98 -1.29 -2.00 -1.89 -0.96 0.01
Operating CF 215.30M 135.66M (246.96M) (431.50M) (335.24M) (182.51M) (63.44M) (70.58M) (96.79M) (73.90M) (37.83M) 10.49M
Total Assets 2.51B 1.66B 1.44B 1.39B 1.24B 932.15M 582.66M 268.17M 214.61M 210.68M 265.24M 123.62M
Total Debt 214.38M 187.12M 441.99M 446.22M 397.23M 281.09M 155.81M 123.51M 123.18M 49.62M 42.09M 26.81M
Cash & Equiv 1.08B 945.59M 642.10M 466.09M 84.39M 48.67M 61.93M 46.41M 12.62M 15.26M 28.95M 87.18M
Book Value 1.71B 1.20B 765.33M 705.74M 653.30M 486.24M 278.71M 32.16M 25.42M 106.48M 184.76M (171.34M)
Return on Equity -0.12 -0.16 -0.57 -0.78 -0.72 -0.47 -0.45 -3.98 -5.36 -0.90 -0.38 N/A
NTRA News
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Oct 13, 2026 04:00 AM · gurufocus.com
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Oct 13, 2026 03:30 AM · businesswire.com
Which Healthcare ETF Is the Better Buy: Fidelity’s Broad FHLC or Invesco’s Biotech-Focused PBE?
Oct 11, 2026 01:46 PM · fool.com
FDA Grants Breakthrough Device Designation for Natera's Multi-Cancer Early Detection Assay
Oct 09, 2026 04:00 AM · businesswire.com
HWG Holdings LP Makes New $9.82 Million Investment in Natera, Inc. $NTRA
Oct 08, 2026 03:13 AM · defenseworld.net
Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
Oct 07, 2026 04:00 AM · businesswire.com
Natera (NASDAQ:NTRA) Hits New 12-Month High – Here’s Why
Oct 06, 2026 06:00 AM · defenseworld.net
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
Oct 06, 2026 05:00 AM · gurufocus.com
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
Oct 06, 2026 04:00 AM · businesswire.com
Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech's Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Oct 05, 2026 04:00 AM · businesswire.com